CytomX Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 7, 2015 /PRNewswire/ -- CytomX Therapeutics, Inc., a biopharmaceutical company developing Probody™ therapeutics for the treatment of cancer, today announced the pricing of its initial public offering of 6,666,667 shares of common stock at an initial public offering price of $12 per share, before underwriting discounts and commissions. In addition, the underwriters have a 30-day option to purchase up to an additional 1,000,000 shares of common stock from CytomX. All shares of common stock are being offered by CytomX. The shares are expected to begin trading on the NASDAQ Global Select Market on October 8, 2015 under the ticker symbol "CTMX."

BofA Merrill Lynch, Jefferies LLC and Cowen and Company LLC are acting as joint book-running managers for the offering.  Oppenheimer & Co. is serving as manager for the offering.  The offering is expected to close on October 14, 2015, subject to the satisfaction of customary closing conditions.

A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission on October 7, 2015. The offering is being made solely by means of a prospectus, copies of which may be obtained from:  BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attention: Prospectus Department, or by email at [email protected]; Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at [email protected]; or Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 631-274-2806 or by fax at 631-254-7140.

Media Contacts: Canale CommunicationsIan Stone[email protected]619-849-5388

Investor Contacts:Trout GroupPete Rahmer[email protected]646-378-2973

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cytomx-announces-pricing-of-initial-public-offering-300156290.html

SOURCE CytomX Therapeutics, Inc.